Treatment of blastic transformation of chronic myelogenous leukemia with mitoxantrone Academic Article Article uri icon


MeSH Major

  • Antibiotics, Antitubercular
  • Mycobacterium tuberculosis
  • Rifampin
  • Tuberculosis, Pulmonary


  • Twenty-four patients with blastic-phase chronic myelogenous leukemia (CML) were treated with mitoxantrone. The patients included 19 whose cells were Philadelphia chromosome (Ph1+) and 5 who were either Ph1- or in whom cytogenetics were not available. Six of the 19 whose cells were Ph1+ responded and one of those who were Ph1- responded. The patients were further characterized into lymphoid or nonlymphoid on the basis of terminal deoxynucleotidyl transferase or morphology. Two of the patients with lymphoid transformation and 3 of those with nonlymphoid transformation responded. In 3 patients post-treatment cytogenetic evaluation revealed the presence of Ph1- metaphases. We conclude that mitoxantrone has modest activity in blCML and that the cytogenetic responses suggest the possibility of greater efficacy in chronic-phase CML.

publication date

  • June 1986



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1007/BF00306753

PubMed ID

  • 3459595

Additional Document Info

start page

  • 189

end page

  • 90


  • 17


  • 2